Oncology
Differentiated Thyroid Carcinoma
20
Pipeline Programs↗
7
Active Trials↗
13
Companies Involved↗
Differentiated Thyroid Carcinoma is an emerging landscape with 20 programs across 13 companies. The most active players are Bristol-Myers Squibb, Gynecologic Oncology Group, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 2 therapies are approved with 5 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 1
No programs
Phase 29
Phase 35
Analysis
Trial Status
14
clinical trials
Unknown status6 · 43%
Recruiting4 · 29%
Active, not recruiting2 · 14%
Not yet recruiting1 · 7%
Completed1 · 7%
Clinical Trials
Trial Activity
14 trials
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
Recruiting·—·Phase 2·NCT06440850·21 enrolled
Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib
Active, not recruiting·—·Phase 2·NCT05007093·20 enrolled
Cognitive Functions During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma
Unknown status·TThe Affiliated Hospital of Inner Mongolia Medical University·N/A·NCT02665325·100 enrolled
Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03167385·20 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)